Moderna rises after US FDA nod for next-gen COVID-19 vaccine
View all comments(0)
Moderna MRNA.O rises 5% to $27.86 premarket
Vaccine maker said U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE, for everyone aged 65 and older
Added mNEXSPIKE also approved for people aged 12-64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention
Noted vaccine expected to be available for the 2025-2026 respiratory virus season
Jefferies says FDA approval "incremental positive" for co as it shows regulator "still reasonable" in approving drugs with good data efficacy, packages
However, expects lower vaccination rates due to "vaccine fatigue and lower public interest in general"
MRNA sheds 36% this year, as of last close
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Rocket Lab Earnings Greatly Exceed Expectations, Ignoring Risks as Stock Price Surges?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.